Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia.

Pediatric blood & cancer·2026
Same author

Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.

Leukemia·2026
Same author

Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.

Leukemia·2025
Same author

T cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges.

The Journal of clinical investigation·2025
Same author

Canagliflozin synergises with serine restriction mediating anti-leukaemic effects in T-cell acute lymphoblastic leukaemia.

Molecular metabolism·2025
Same author

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.

Blood·2025

Related Experiment Video

Updated: Jul 8, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Methotrexate Neurological Toxicities: Current State-of-the-Art.

Abbie Wilson1, Christina Halsey1

  • 1School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, G61 1QH Glasgow, UK.

British Journal of Hospital Medicine (London, England : 2005)
|July 7, 2026
PubMed
Summary
This summary is machine-generated.

Methotrexate (MTX) can cause neurotoxicity, affecting patients on high-dose, intrathecal, or even low-dose treatments. Recognizing and managing these neurological side effects is crucial for patient care.

Keywords:
drug-related side effects and adverse reactionsleukemiamethotrexatenervous system diseasesneurotoxicity syndromes

Related Experiment Videos

Last Updated: Jul 8, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Area of Science:

  • Neuroscience
  • Pharmacology
  • Oncology

Background:

  • Methotrexate (MTX) is a vital anti-folate chemotherapy and anti-inflammatory agent.
  • While MTX toxicity in organs like bone marrow, liver, and kidneys is well-known, its neurotoxic effects are less recognized.
  • Neurotoxicity can occur across various MTX dosing regimens, including low-dose treatments.

Purpose of the Study:

  • To provide a comprehensive review of methotrexate-induced neurotoxicity.
  • To enhance physician awareness regarding the presentation and management of MTX neurotoxicity.
  • To identify current research and evidence gaps in MTX neurotoxicity treatment and prevention.

Main Methods:

  • Literature review of existing studies on methotrexate neurotoxicity.
  • Analysis of reported clinical presentations and outcomes.
  • Synthesis of current understanding regarding mechanisms, diagnosis, and management strategies.

Main Results:

  • MTX neurotoxicity presents with diverse symptoms, from acute (headache, somnolence) to sub-acute (seizures, stroke-like symptoms) and chronic (cognitive/behavioral issues).
  • Stroke-like symptoms can manifest days post-administration, necessitating awareness from acute care providers.
  • The precise mechanisms underlying MTX neurotoxicity are not fully understood.

Conclusions:

  • Increased physician awareness of MTX neurotoxicity is essential for timely diagnosis and management.
  • Current treatments and preventative strategies for MTX neurotoxicity lack robust evidence, highlighting a critical need for further research.
  • Future research should focus on elucidating mechanisms and developing effective interventions for MTX neurotoxicity.